Marek Pawlikowski Selected Research

somatostatin receptor type 1

9/2011	Differential expression of somatostatin receptor subtype-related genes and proteins in non-functioning and functioning adrenal cortex adenomas.
1/2011	Expression of somatostatin receptor subtypes in primary and recurrent gonadotropinomas: are somatostatin receptors involved in pituitary adenoma recurrence?
1/2010	SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
7/2009	Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
1/2009	Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.
2/2003	Perspectives of new potential therapeutic applications of somatostatin analogs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marek Pawlikowski Research Topics

Disease

37	Neoplasms (Cancer) 09/2020 - 01/2000
29	Pituitary Neoplasms (Pituitary Adenoma) 01/2020 - 01/2000
19	Adenoma (Adenomas) 01/2020 - 01/2000
6	Prolactinoma (Prolactinomas) 07/2009 - 01/2004
5	Acromegaly 01/2016 - 03/2009
3	Prostatic Neoplasms (Prostate Cancer) 01/2011 - 11/2004
3	Pituitary ACTH Hypersecretion 03/2009 - 01/2006
2	Hyperprolactinemia 01/2012 - 11/2006
2	Growth Hormone-Secreting Pituitary Adenoma 03/2010 - 05/2008
1	COVID-19 01/2021
1	Frailty 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Infections 01/2021
1	Obesity 01/2021
1	Osteoporosis 01/2021
1	Sarcopenia 01/2021
1	Thyroid Neoplasms (Thyroid Cancer) 01/2019
1	Adrenocortical Adenoma (Disease, Conn's) 09/2011
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2010
1	Hyperplasia 01/2009
1	Cushing Syndrome 06/2008
1	Pheochromocytoma 01/2008
1	Breast Neoplasms (Breast Cancer) 06/2006
1	Atrophy 06/2005
1	Sarcoma (Soft Tissue Sarcoma) 01/2005

Drug/Important Bio-Agent (IBA)

13	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2016 - 01/2003
11	Pituitary HormonesIBA 01/2020 - 01/2003
10	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2016 - 01/2000
9	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2003
9	MelatoninIBA 01/2021 - 01/2000
9	Hormones (Hormone)IBA 01/2021 - 01/2000
9	AntibodiesIBA 01/2020 - 01/2003
7	ProlactinIBA 01/2020 - 01/2000
7	AngiotensinsIBA 08/2012 - 10/2002
6	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2020 - 02/2005
6	somatostatin receptor type 1IBA 09/2011 - 02/2003
6	Octreotide (Sandostatin)FDA LinkGeneric 03/2010 - 01/2000
6	Estrogens (Estrogen)FDA Link 06/2006 - 10/2002
4	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021 - 01/2006
4	GonadotropinsIBA 01/2021 - 01/2005
4	FSH Receptors (FSH Receptor)IBA 12/2015 - 10/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2012 - 01/2005
4	Diethylstilbestrol (Stilbestrol)FDA Link 01/2012 - 05/2003
4	Protein Isoforms (Isoforms)IBA 01/2010 - 01/2003
4	Melatonin Receptors (Melatonin Receptor)IBA 01/2009 - 04/2002
4	LigandsIBA 06/2006 - 04/2002
3	Growth Hormone (Somatotropin)IBA 01/2020 - 02/2008
3	ParaffinIBA 01/2019 - 01/2008
3	Peptides (Polypeptides)IBA 08/2012 - 11/2004
3	PPAR gammaIBA 03/2009 - 01/2005
3	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2009 - 04/2002
2	Luteinizing Hormone (Lutropin)FDA LinkGeneric 09/2020 - 01/2020
2	Follicle Stimulating Hormone (Follitropin)FDA Link 09/2020 - 01/2020
2	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2020 - 01/2016
2	EnzymesIBA 01/2020 - 01/2005
2	Ki-67 Antigen (Ki 67 Antigen)IBA 01/2014 - 01/2011
2	prothymosin alphaIBA 01/2014 - 01/2009
2	Nitric Oxide Synthase (NO Synthase)IBA 01/2012 - 01/2003
2	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 09/2010 - 01/2004
2	lanreotide (Somatuline)FDA Link 07/2009 - 01/2000
2	Biological ProductsIBA 04/2009 - 05/2008
2	Rosiglitazone (Avandia)FDA Link 03/2009 - 02/2005
2	CGP 52608IBA 06/2006 - 05/2003
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2006 - 01/2005
2	Angiotensin IIIBA 11/2004 - 10/2002
2	SuspensionsIBA 04/2002 - 01/2000
2	Bromodeoxyuridine (BrdU)IBA 04/2002 - 01/2000
1	Angiotensin-Converting Enzyme 2IBA 01/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021
1	ElementsIBA 01/2021
1	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2021
1	alpha Subunit Glycoprotein HormonesIBA 01/2020
1	Insulin-Like PeptidesIBA 01/2020
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2020
1	LH Receptors (LH Receptor)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2014
1	AT4 receptorIBA 08/2012
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2012
1	p38 Mitogen-Activated Protein KinasesIBA 01/2012
1	somatostatin receptor 2IBA 09/2011
1	Type 1 Angiotensin ReceptorIBA 04/2009
1	Peroxisome ProliferatorsIBA 03/2009
1	luzindoleIBA 01/2009
1	CytokinesIBA 11/2007
1	Dopamine Agonists (Dopamine Agonist)IBA 11/2006
1	Cabergoline FDA LinkGeneric 11/2006
1	2,4-thiazolidinedione (thiazolidinedione)IBA 06/2006
1	Methotrexate (Mexate)FDA LinkGeneric 06/2006
1	Dehydroepiandrosterone (DHEA)IBA 06/2005
1	SteroidsIBA 06/2005
1	ThiazolidinedionesIBA 02/2005
1	EndostatinsIBA 01/2005
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2005
1	Radioisotopes (Radionuclides)IBA 12/2004
1	AminopeptidasesIBA 11/2004
1	AndrogensIBA 11/2004

Therapy/Procedure

5	Therapeutics 01/2016 - 04/2002
1	Drug Therapy (Chemotherapy) 01/2016
1	Prostheses and Implants (Prosthesis) 01/2005
1	Arthroplasty 01/2005